文献速递脑血管病

依达拉奉右莰醇治疗急性缺血性卒中的临床与安全性结局:多中心前瞻性队列研究

Clinical and Safety Outcomes of Edaravone Dexborneol in Acute Ischemic Stroke: A Multicenter, Prospective, Cohort Study.
PubMed 文献 · Neurology · 2025-08-05

该研究为在中国72家中心开展的前瞻性真实世界队列研究,纳入4401例发病14天内、病前mRS 0-1分的急性缺血性卒中患者,其中3017例接受依达拉奉右莰醇治疗。多因素校正后,暴露组90天良好功能结局(mRS 0-1)比例显著更高(68.6% vs 66.0%,aOR 1.23,95%CI 1.06-1.43),症状性颅内出血和90天全因死亡率两组相似。

要点

  • 依达拉奉右莰醇与急性缺血性卒中90天良好功能结局独立相关(aOR 1.23)。
  • 症状性颅内出血和90天死亡率两组无显著差异,安全性需更大样本验证。
  • 结果来自中国真实世界队列,需在其他人群中进一步验证。

核心结论

  • 在中国急性缺血性卒中患者中,依达拉奉右莰醇与90天良好功能结局(mRS 0-1)显著相关。

研究设计与样本

  • 前瞻性、多中心、真实世界队列研究,中国72家中心,2023年1月14日至7月4日入组。
  • 纳入年龄≥18岁、发病14天内、病前mRS 0或1分的急性缺血性卒中患者,共4401例。
  • 暴露组3017例(68.6%)接受依达拉奉右莰醇,非暴露组1384例未接受。
  • 采用多因素logistic回归、倾向性评分匹配(PSM)和逆概率治疗加权(IPTW)分析。

主要发现

  • 暴露组90天良好功能结局比例68.6%(2071/3017),非暴露组66.0%(914/1384),aOR 1.23(95%CI 1.06-1.43)。
  • 症状性颅内出血率暴露组0.4%、非暴露组0.6%,aOR 0.44(95%CI 0.14-1.44)。
  • 90天全因死亡率暴露组2.1%、非暴露组3.3%,调整后风险比0.89(95%CI 0.58-1.37)。
  • PSM和IPTW分析结果与多因素校正模型一致。

临床怎么用

  • 对于符合入组条件的急性缺血性卒中患者,依达拉奉右莰醇可能改善90天功能结局。
  • 该研究为观察性证据(Class III),不能确立因果关系,临床决策需结合个体情况。

局限性

  • 研究为观察性队列,存在残余混杂可能。
  • 结果来自中国人群,需在其他人群中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Although edaravone dexborneol, a multitarget cytoprotective drug, has demonstrated benefits in previous clinical trials, its actual clinical efficacy and safety in patients with acute ischemic stroke (AIS) remain unclear. This study aimed to test the hypothesis that edaravone dexborneol is associated with better outcomes in patients with AIS in real-world clinical practice. METHODS: We conducted a prospective, multicenter, real-world cohort study at 72 centers in China from January 14 to July 4, 2023. We included patients age 18 years or older, with AIS within 14 days of onset, and a prestroke modified Rankin Scale (mRS) of 0 or 1. Patients were divided into those receiving edaravone dexborneol (the exposed group) or not (the unexposed group). Clinical outcomes included favorable functional outcome (mRS score 0-1) at 90 days, symptomatic intracerebral hemorrhage (sICH) during the hospital, and all-cause mortality within 90 days. Multivariable logistic regression, propensity score matching (PSM), and inverse probability of treatment weighting (IPTW) analyses were conducted. RESULTS: Of 4,401 participants (2,904 men [66.8%]; median [interquartile range] age, 65 [57-72] years), 3,017 (68.6%) were treated with edaravone dexborneol. The exposed group was younger (65 [56-72] years vs 66 [58-74] years), had higher NIH Stroke Scale (3 [2-7] vs 3 [1-5]), and had shorter time from onset to admission (7.0 [2.5-24.0] hours vs 10.4 [2.8-48.0] hours). The exposed group had a higher proportion of patients with favorable functional outcome at 90 days compared with the unexposed group (68.6% [2,071/3,017] vs 66.0% [914/1,384], adjusted odds ratio [aOR] 1.23 [95% CI 1.06-1.43]). Moreover, sICH rates (0.4% vs 0.6%, aOR 0.44 [95% CI 0.14-1.44]) and mortality within 90 days (2.1% vs 3.3%, adjusted hazard ratio 0.89 [95% CI 0.58-1.37]) were similar in both groups. PSM and IPTW analyses yielded results consistent with the multivariate adjustment model. DISCUSSION: In this observational cohort study involving Chinese patients with AIS, edaravone dexborneol was associated with significantly better functional outcome at 90 days. Verification of our findings is warranted in other populations. TRIAL REGISTRATION INFORMATION: This trial is registered with Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke, number NCT05644223; submitted for registration on November 30, 2022; first patient enrollment was on January 14, 2023. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that treatment of patients with AIS with edaravone dexborneol is associated with significantly better functional outcome at 90 days measured using the mRS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ma G, Mo R, Yao X, et al. Clinical and Safety Outcomes of Edaravone Dexborneol in Acute Ischemic Stroke: A Multicenter, Prospective, Cohort Study. Neurology. 2025. PMID: 40763317. doi:10.1212/WNL.0000000000213949

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。